Data Silos

Agentic AI is transforming life sciences marketing, moving beyond basic prompts to autonomously manage complex initiatives. This shift could unlock significant economic value by 2028, with executives planning widespread integration. In pharmaceutical marketing, these AI agents can overcome fragmented data challenges, empowering sales reps with real-time intelligence and personalized engagement plans for healthcare professionals. Success hinges on “AI-ready data” for accelerated decision-making, scalable personalization, and measurable ROI, though regulatory hurdles remain.

IBM’s report identifies data silos as the primary obstacle to enterprise AI adoption, hindering seamless integration and collaboration. Fragmented data across departments leads to prolonged data cleansing projects, delaying insights and ROI. The report suggests distributed data architectures like data mesh and fabric, alongside “data products,” to improve accessibility. Talent shortages and governance complexities also pose challenges. Success hinges on breaking down silos, democratizing data literacy, and treating data as a strategic asset to scale AI across the organization.